SOPHiA GENETICS (SOPH) CSO sells 624 shares to cover RSU taxes

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert sold 624 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 6, 2026 at prices around $4.86 per share and were executed solely to cover tax obligations from recently vested restricted stock units.

After these tax-related sales, Puylaert directly holds 148,230 Ordinary Shares, indicating that only a very small portion of his equity position was used for the "sell to cover" transactions, which the company describes as non-discretionary rather than voluntary market trades.

Insights

Insider transactions analyst

Routine tax-related sell-to-cover, small versus ongoing holdings.

Chief Sales Officer Kevin Puylaert sold a total of 624 Ordinary Shares of SOPHiA GENETICS SA on April 6, 2026 at prices near $4.86 per share. Footnotes state these were open-market sales to satisfy tax obligations from restricted stock unit vesting.

The filing describes the trades as "sell to cover" and explicitly notes they do not represent discretionary trades, which reduces their signaling value about management’s view of the stock. After the transactions, Puylaert still directly owns 148,230 Ordinary Shares, so the dispositions represent a minor fraction of his visible equity position.

Insider Trade Summary

Net Seller: 624 shares ($3,032)

Net Sell 3 txns

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 624 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	548	$4.86	$3K
Sale	Ordinary Shares	46	$4.86	$223.56
Sale	Ordinary Shares	30	$4.83	$144.90

Holdings After Transaction: Ordinary Shares — 148,306 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Key Figures

Shares sold: 624 shares Sale price (primary): $4.86 per share Sale price (additional): $4.83 per share +2 more

5 metrics

Shares sold 624 shares Total Ordinary Shares sold on April 6, 2026

Sale price (primary) $4.86 per share Open-market sales of Ordinary Shares

Sale price (additional) $4.83 per share Smaller portion of Ordinary Share sales

Shares held after 148,230 shares Direct Ordinary Share ownership after transactions

Role Chief Sales Officer Officer title of reporting person

Key Terms

sell to cover, restricted stock units, open market

3 terms

sell to cover financial

"The sales were effected as a "sell to cover" transaction and do not represent discretionary trades."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"tax obligations in connection with the vesting of restricted stock units on April 2, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/06/2026		S		548(1)	D	$4.86	148,306	D
Ordinary Shares	04/06/2026		S		46(1)	D	$4.86	148,260	D
Ordinary Shares	04/06/2026		S		30(2)	D	$4.83	148,230	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

2. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) executive Kevin Puylaert report in this Form 4?

Kevin Puylaert, Chief Sales Officer of SOPHiA GENETICS, reported selling 624 Ordinary Shares of SOPH on April 6, 2026. These transactions were open-market sales executed solely to cover tax obligations arising from the recent vesting of his restricted stock units.

How many SOPHiA GENETICS (SOPH) shares did Kevin Puylaert sell and at what prices?

Kevin Puylaert sold 624 Ordinary Shares of SOPHiA GENETICS. Most shares were sold at a price of $4.86 per share, with a smaller portion sold at $4.83. All transactions occurred on April 6, 2026 as part of tax-related sell-to-cover activity.

Why were Kevin Puylaert’s SOPHiA GENETICS (SOPH) shares sold according to the Form 4 footnotes?

The footnotes explain the shares were sold in the open market to satisfy tax obligations linked to restricted stock units that vested on April 2 and April 3, 2026. The company characterizes these as "sell to cover" transactions, not discretionary trading decisions by Puylaert.

How many SOPHiA GENETICS (SOPH) shares does Kevin Puylaert hold after these transactions?

Following the April 6, 2026 transactions, Kevin Puylaert directly holds 148,230 Ordinary Shares of SOPHiA GENETICS. This indicates that the 624 shares sold for tax purposes represent only a very small portion of his overall disclosed equity position in the company.

Are Kevin Puylaert’s SOPHiA GENETICS (SOPH) share sales considered routine or discretionary?

The filing states the share sales were effected as "sell to cover" transactions to pay tax obligations from restricted stock unit vesting. It further clarifies that these do not represent discretionary trades, suggesting they are routine, tax-driven dispositions rather than voluntary market timing decisions.